Central nervous system stimulants and drugs that suppress appetite

Side Effects of Drugs Annual

Volumn 36, Issue , 2014, Pages 1-9

  Aagaard, Lise ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adverse reactions; Alzheimer's disease; Amfetamine; Amphetamines; Appetite suppressants; Armodafinil; Atomoxetine; Benfluorex; Caffeine; Dexamfetamine; Donepezil; Fenfluramine; Galantamine; Metamfetamine; Methylphenidate; Methylxanthines; Modafinil; Paramethoxyamfetamine; Paramethoxymetamfetamine; Phentermine; Rimonabant; Rivastigmine; Sibutramine; Theophylline

Indexed keywords

EID: 84918504163     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63407-8.00001-0     Document Type: Chapter

References (84)

1. Mick E., McManus D.D., Goldberg R.J. Meta-analysis of increased hearth rate and blood pressure associated with CNS stimulant therapy. Eur Neuropsychopharmacol 2013, 23(6):534-541.
2. Schelleman H., Bilker W.B., Kimmel S.E., Daniel G.W., Newcomb C., Guevara J.P., et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One 2013, 8(1):e52991.
3. Olfson M., Huang C., Gerhard T., Winterstein A.G., Crystal S., Allison P.D., Marcus S.C. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012, 51:147-156.
4. Product information: Dexedrine Spansule (R), dextroamphetamine. Amedra pharmaceuticals LLC.
5. Product information: Adderall (R), mixed amphetamine salts. Saint-Laurent, Quebec: Shire Canada, Inc.
6. Lakhan S.E., Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav 2012, 2(5):661-677.
7. Cortese S., Holtmann M., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry and Allied Disciplines 2013, 54(3):227-246.
8. Babcock T., Dirks B., Adeyi B., Scheckner B. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacol Toxicol 2012, 13:18.
9. Product Information: Vyvanse(R), lisdexamfetamine dimesylate. Saint-Laurent, Quebec: Shire LLC.
10. Martin P.T., Corcoran M., Zhang P., Katic A. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder. Clin Drug Invest 2014, 34(2):147-157.
11. Montani D., Seferian A., Savale L., Simonneau G., Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respir Rev 2013, 22(129):244-250.
12. Parrott A.C. Human psychobiology of MDMA or 'Ecstasy': an overview of 25years of empirical research. Human Psychopharmacol 2013, 28(4):289-307.
13. Michael White C. How MDMA's pharmacology and pharmacokinetics drive desired effects and harms. J Clin Pharmacol 2014, 54(3):245-252.
14. Leibel S., Bloomberg G. Attention-deficit/hyperactivity disorder stimulant medication reaction masquerading as chronic cough. Ann Allergy Asthma Immunol 2013, 111(2):82-83.
15. Ford J.B., Albertson T.E., Owen K.P., Sutter M.E., McKinney W.B. Acute, sustained chorea in children after supratherapeutic dosing of amphetamine-derived medications. Pediatr Neurol 2012, 47:216-218.
16. Goez H.R., Scott O., Nevo N., Beckett-Back O., Zelnik N. Using the test of variables of attention to determine the effectiveness of modafinil in children with attention-deficit hyperactivity disorder (ADHD): a prospective methylphenidate-controlled trial. J Child Neurol 2012, 27(12):1547-1552.
17. Chevassus H., Farrett A., Gagnol J.P., Poncon C.A., Costa F., Roux C., et al. Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). Eur J Clin Pharmacol 2013, 69:779-787.
18. Jafarinia M., Mohammadi M.R., Modabbernia A., Ashrafi M., Khajavi D., Tabrizi M., et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol Clin Exp 2012, 27:411-418.
19. Rosenberg P.B., Lanctot K.L., Drye L.T., Hermann N., Scherer R.W., Bachmann D.L., et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013, 74:810-816. ADMET Investigators.
20. Buitelaar J.K., Trott G.E., Hofecker M., Waechter S., Berwaerts J., Dejonkheere J., et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol 2012, 15:1-13.
21. Schelleman H., Bilker W.B., Kimmel S.E., Daniel G.W., Newcomb C., Guevara J.P., et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012, 169(2):178-185.
22. Westover A.N., Nakonezny P.A., Winhusen T., Adinoff B., Vongpatanasin W. Risk of methylphenidate-induced prehypertension in normotensive adult smokers with ADHD. J Clin Hypertens (Greenwich) 2013, 15:124-132.
23. Product information: Ritalin(R), methylphenidate. Gainesville, GA: Novartis.
24. Dideriksen D., Pottegård A., Hallas J., Aagaard L., Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol 2013, 112:73-76.
25. Ensat F., Edelbauer M., Wechselberger G. Unilateral gynecomastia in a prepubertal boy. Eur J Pediatr 2012, 171(1):197.
26. Oosterhuis I., Heijting L., van Puijenbroek E. Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors. Eur J Clin Pharmacol 2012, 68(10):1461-1462.
27. Marti G., Fattinger K., Zimmermann H., Exadaktylos A. Orofacial dyskinesia induced by nasal Ritalin(R) (methylphenidate) sniffing: a rare case report from Switzerland. Hum Exp Toxicol 2013, 32:332-334.
28. Yilmaz A.E., Donmez A., Orun E., Tas T., Isik B., Sonmez F.M. Methylphenidate-induced acute orofacial and extremity dyskinesia. J Child Neurol 2013, 28(6):781-783.
29. Kelly B.D., Lundon D.J., McGuinness D., Brady C.M. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol 2013, 9(1):e1-e2.
30. Ghasri P., Gattu S., Saedi N., Ganesan A. Chemical leukoderma following application of transdermal methylphenidate patch. J Am Acad Dermatol 2012, 66:e237-e238.
31. Caffeine drug information. [accessed 07/21/2014]. http://www.micromedexsolutions.com.une.idm.oclc.org/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/54C377/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/DCB367/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/eviden.
32. Yen M., Ewald M.B. Toxicity of weight loss agents. J Med Toxicology 2012, 8(2):145-152.
33. Miller M., Kumar A.B., Callison C.R. Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach. Neuroradiology 2012, 54(1):77-79.
34. Wilson R.E., Kado H.S., Samson R., Miller A.B. A case of caffeine-induced coronary artery vasospasm of a 17-year-old male. Cardiovasc Toxicol 2012, 12(2):175-179.
35. Bioh G., Gallagher M.M., Prasad U. Survival of a highly toxic dose of caffeine. BMJ Case Rep February 8, 2013, pii:bcr2012007454. 10.1136/bcr-2012-007454.
36. Wietecha L.A., Ruff D.D., Allen A.J., Greenhill L.L., Newcorn J.H. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psyc 2013, 74(12):1217-1223.
37. Product information: Strattera(R), atomoxetine. Indianapolis, IN: Lilly USA, LLC.
38. Hilton-Jones D., Bowler M., Lochmueller H., Longman C., Petty R., Roberts M., et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1-the patients' perspective. Neuromuscul Disord 2012, 22(7):597-603.
39. Product information: Nuvigil(R), armodafinil. North Wales, PA: Cephalon, Inc.
40. Sheng P., Hou L., Wang X., Wang X., Huang C., Yu M., et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PloS One 2013, 8(12):e81802.
41. Darwish M., Bond M., Hellriegel E.T., Youakim J.M., Yang R., Robertson P. Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study. J Clin Pharmacol 2012, 52(9):1399-1409.
42. Rudhran V., Manjunatha N., John J.P. High-dose, self-administered modafinil-related psychosis: is it the pedal in the prodrome of psychosis?. J Clin Psychopharmacol 2013, 33:576-577.
43. Marechaux S., Jeu A., Jobic Y., Ederhy S., Donald E., Reant P., et al. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study. Arch Cardiovasc Dis 2013, 106(6-7):349-356.
44. Product information: Pondimin(R), fenfluramine. Richmond, VA: AH Robins Company.
45. Droogmans S., Cosyns B., Van Camp G. Benfluorex: the last chapter of drug-induced valvular heart disease?. Eur J Echocardiogr 2011, 12(4):263-264.
46. Nau J.Y. Quelles etaient les indications du Mediator en 1979? [What were the indications for the Mediator in 1979?]. Rev Med Suisse 2011, 7(281):374-375.
47. ®), our vigilance in question.]. Presse Med 2011, 40(5):459-461.
48. Mauduit L. Mediator, la police du medicament en question. [Mediator, the police of the medication in question.]. Soins 2011, (754):6.
49. ®: analyse d'une crise de sécurité sanitaire. Diabetes Metab 2011, 37(3):169-175.
50. Waller P., Evans S. Mediator: who's to blame?. Lancet 2011, 377(9782):2002-2003.
51. Braillon A. Mediator: who's to blame?. Lancet 2011, 377(9782):2003-2004.
52. Vincent L., Guardiola B., Tsouderos Y., Canet E. Mediator: who's to blame?. Lancet 2011, 377(9782):2003.
53. Bondon-Guitton E., Prévôt G., Didier A., Montastruc J.L. Pulmonary arterial hypertension and benfluorex: 5 case reports. Thérapie 2011, 66(2):135-138.
54. Etienne Y., Jobic Y., Frachon I., Fatemi M., Castellant P., Quintin-Roué I. Mitral and aortic valvular disease associated with benfluorex use. J Heart Valve Dis 2011, 20(3):348-350.
55. Tribouilloy C., Rusinary D., Marechaux S., Jeu A., Ederhy S., Donald E., et al. Increased risk of left heart valve regurgitation associated with benflourex use in patients with diabetes mellitus: a multicenter study. Circulation 2012, 126(24):2852-2858.
56. Ceulemans B., Boel M., Leyssens K., Van Rossem C., Neels P., Jorens P.G., et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012, 53:1131-1139.
57. Steffen K., Kolotkin Ronette L. A review of the combination of phentermine and topiramate extended-release for weight loss. Comb Prod Ther 2012, 2:3. 10.1007/s13556-012-0003-1.
58. Winslow D.H., Bowden C.H., DiDonato K.P., McCullough P.A. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012, 35(11):1529-1539.
59. Product information: phentermine. Philadelphia, PA: Lannett Holdings, Inc.
60. Tobbia P., Norris L.A., Klima L.D., Tobbia P., Norris L.A., Klima L.D. Ventricular fibrillation coinciding with phentermine initiation. BMJ Case Rep October 12, 2012, pii:bcr2012006410. 10.1136/bcr-2012-006410.
61. Dziewierz A., Olszanecka A., Wiliński J., Rakowski T., Kleczyński P., Dubiel J.S., et al. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine. Int J Cardiol 2012, 160(2):e31-e32.
62. Van Gaal L., Pi-Sunyer X., Despres J.P., McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(suppl. 2):S229-S240.
63. Product information: Meridia(R), sibutramine hydrochloride. North Chicago, IL: Abbott Laboratories.
64. Kim K.K., Cho H.J., Kang H.C., Youn B.B., Lee K.R. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006, 47(5):614-625.
65. Astrup A., Madsbad S., Breum L., Jensen T.J., Kroustrup J.P., Larsen T.M. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9653):1906-1913.
66. Astrup A., Madsbad S., Breum L., Jensen T.J., Kroustrup J.P., Larsen T.M. Under-reporting of adverse effects of tesofensine. Lancet 2013, 382(9887):127.
67. Segers K., Cytryn E., Surquin M. Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study. J Clin Psychopharmacol 2012, 32(3):412-415.
68. Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. Psychogeriatrics 2012, 12:165-171.
69. Kulkantrakorn K., Tanyakitpisal P., Towanabut S., Dejthevaporn C., Rangseekajee P., Pongpakdee S., et al. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand. Psychogeriatrics 2013, 13:1-8.
70. Product information: Exelon(R), rivastigmine. East Hanover, NJ: Novartis.
71. Emre M., Poewe W., De Deyn P.P., Barone P., Kulisevsky J., Pourcher E., et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clinical Neuropharmacol 2014, 37(1):9-16.
72. Seibert J., Tracik F., Articus K., Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatr Dis Treat 2012, 8:141-147.
73. Sheen V.L., Shankar M., Marin-Valencia I., Bridgemohan C.H., Torres A.R. Methylphenidate and continuous spike and wave during sleep in a child with attention deficit hyperactivity disorder. Pediatr Neurol 2013, 49(1):54-57.
74. Hadono Y., Ogawa H., Wakeyma T., Iwami T., Kimura M., Mochizuki M., et al. J of Cardiol Cases 2013, 8:e69-e71.
75. Yatabe Y., Hashimoto M., Kaneda K., Honda K., Ogawa Y., Yuuki S., et al. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5mg donepezil: a preliminary study. Psychogeriatrics 2013, 13(2):88-93.
76. Doody R.S., Geldmacher D.S., Farlow M.R., Sun Y., Moline M., Mackell J. Efficacy and safety of donepezil 23mg versus donepezil 10mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord 2012, 33(2-3):164-173.
77. Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012, 366(10):893-903.
78. Product information: Aricept(R), donepezil. Kirkland, Quebec: Pfizer.
79. Ikeda M., Mori E., Kosaka K., Iseki E., Hashimoto M., Matsukawa N., et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013, 36(3-4):229-241.
80. Wolff M.L. Case report: post-traumatic memories triggered by donepezil in a dose-dependent pattern. Am J Geriatr Pharmacother 2012, 10:219-222.
81. Hager K., Baseman A.S., Nye J.S., Brashear H.R., Han J.S, Sano M., et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat 2014, 10:391-401.
82. Product information: Razadyne(R), galantamine. Toronto, ON: Janssen Inc.
83. Caramelli P., Laks J., Palmini A.L., Nitrini R., Chaves M.L, Forlenza O.V., et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arq Neuropsiquiatr 2014, 72(6):411-417.
84. Product information: Desoxyn(R), methamphetamine hydrochloride. Deerfield, IL: Ovation Pharmaceuticals Inc.